Profile of secukinumab in the treatment of psoriasis: current perspectives

References

• RachakondaTDSchuppCWArmstrongAWPsoriasis prevalence among adults in the United StatesJ Am Acad Dermatol201470351251624388724
   PubMed Web of Science ®Google Scholar
• GladmanDDAntoniCMeasePCleggDONashPPsoriatic arthritis: epidemiology, clinical features, course, and outcomeAnn Rheum Dis200564Suppl 2ii14ii1715708927
   PubMed Web of Science ®Google Scholar
• AricanOAralMSasmazSCiragilPSerum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severityMediators Inflamm20052005527327916258194
   PubMed Web of Science ®Google Scholar
• HarperEGGuoCRizzoHTh17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesisJ Invest Dermatol200912992175218319295614
   PubMed Web of Science ®Google Scholar
• OuelletteAJPaneth cells and innate mucosal immunityCurr Opin Gastroenterol201026654755320693892
   PubMed Web of Science ®Google Scholar
• WilsonNJBonifaceKChanJRDevelopment, cytokine profile and function of human interleukin 17-producing helper T cellsNat Immunol20078995095717676044
   PubMed Web of Science ®Google Scholar
• KollsJKLindénAInterleukin-17 family members and inflammationImmunity200421446747615485625
   PubMed Web of Science ®Google Scholar
• HueberWPatelDDDryjaTEffects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitisSci Transl Med20102525272
   Web of Science ®Google Scholar
• BaraliakosXBorahBBraunJLong-term effects of secukinumab on MRI findings in relation to clinical efficacy in subjects with active ankylosing spondylitis: an observational studyAnn Rheum Dis Epub862015
   Google Scholar
• LetkoEYehSFosterCSEfficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapyOphthalmology2015122593994825638011
   PubMed Web of Science ®Google Scholar
• BaetenDBaraliakosXBraunJAnti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trialLancet201338299061705171324035250
   PubMed Web of Science ®Google Scholar
• GenoveseMCDurezPRichardsHBEfficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled studyAnn Rheum Dis201372686386922730366
   PubMed Web of Science ®Google Scholar
• BraunJKiltzUHeldmannFBaraliakosXEmerging drugs for the treatment of axial and peripheral spondyloarthritisExpert Opin Emerg Drugs201520111425575936
   PubMed Web of Science ®Google Scholar
• HueberWSandsBELewitzkySSecukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trialGut201261121693170022595313
   PubMed Web of Science ®Google Scholar
• Highlights of Prescribing Information [Revised January 1, 2015] Available from: http://www.pharma.us.novartis.com/product/pi/pdf/cosentyx.pdfAccessed February 23, 2015
   Google Scholar
• BlauveltAPrinzJCGottliebABSecukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)Br J Dermatol2015172248449325132411
   PubMed Web of Science ®Google Scholar
• PaulCLacourJPTedremetsLEfficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)J Eur Acad Dermatol Venereol20152961082109025243910
   PubMed Web of Science ®Google Scholar
• WangWWangEQBalthasarJPMonoclonal antibody pharmacokinetics and pharmacodynamicsClin Pharmacol Ther200884554855818784655
   PubMed Web of Science ®Google Scholar
• StrandVKosinskiMGnanasakthyAMallyaUMpofuSSecukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholdsHealth Qual Life Outcomes2014123124597620
   PubMed Web of Science ®Google Scholar
• PappKALangleyRGSigurgeirssonBEfficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging studyBr J Dermatol2013168241242123106107
   PubMed Web of Science ®Google Scholar
• RichPSigurgeirssonBThaciDSecukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding studyBr J Dermatol2013168240241123362969
   PubMed Web of Science ®Google Scholar
• MrowietzULeonardiCLGirolomoniGSecukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: a randomized, double-blind, noninferiority trial (SCULPTURE)J Am Acad Dermatol20157312736.e125982539
   PubMed Web of Science ®Google Scholar
• LangleyRGElewskiBELebwohlMSecukinumab in plaque psoriasis – results of two phase 3 trialsN Engl J Med2014371432633825007392
   PubMed Web of Science ®Google Scholar
• LønnbergASZachariaeCSkovLTargeting of interleukin-17 in the treatment of psoriasisClin Cosmet Investig Dermatol20147251259
   PubMedGoogle Scholar
• OhtsukiMMoritaAAbeMSecukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 studyJ Dermatol201441121039104625354738
   PubMed Web of Science ®Google Scholar
• ThaçiDBlauveltAReichKSecukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trialJ Am Acad Dermatol201573340040926092291
   PubMed Web of Science ®Google Scholar
• ThaçiDHumeniukJFrambachYSecukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE)Br J Dermatol2015173377778725823958
   PubMed Web of Science ®Google Scholar
• McInnesIBSieperJBraunJEfficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trialAnn Rheum Dis201473234935623361084
   PubMed Web of Science ®Google Scholar
• MeasePJMcInnesIBKirkhamBSecukinumab inhibition of interleukin-17a in patients with psoriatic arthritisN Engl J Med2015373141329133926422723
   PubMed Web of Science ®Google Scholar
• McInnesIBMeasePJKirkhamBSecukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trialLancet201538699991137114626135703
   PubMed Web of Science ®Google Scholar
• GottliebABLangleyRGPhilippSSecukinumab improves physical function in subjects with plaque psoriasis and psoriatic arthritis: results from two randomized, phase 3 trialsJ Drugs Dermatol201514882183326267726
   PubMed Web of Science ®Google Scholar
• HuangWNaLFidelPLSchwarzenbergerPRequirement of interleukin-17A for systemic anti-Candida albicans host defense in miceJ Infect Dis2004190362463115243941
   PubMed Web of Science ®Google Scholar
• FarhangianMEFeldmanSRImmunogenicity of biologic treatments for psoriasis: therapeutic consequences and the potential value of concomitant methotrexateAm J Clin Dermatol201516428529425963062
   PubMed Web of Science ®Google Scholar
• LeyKSmithEStarkMAIL-17A-producing neutrophil-regulatory Tn lymphocytesImmunol Res200634322924216891673
   PubMed Web of Science ®Google Scholar
• ChioatoANosedaEStevensMGaitatzisNKleinschmidtAPicaudHTreatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center studyClin Vaccine Immunol201219101597160222875601
   PubMed Web of Science ®Google Scholar
• LeonardiCMathesonRZachariaeCAnti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasisN Engl J Med2012366131190119922455413
   PubMed Web of Science ®Google Scholar
• PappKALeonardiCMenterABrodalumab, an anti-interleukin-17-receptor antibody for psoriasisN Engl J Med2012366131181118922455412
   PubMed Web of Science ®Google Scholar
• GriffithsCEReichKLebwohlMComparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trialsLancet2015386999354155126072109
   PubMed Web of Science ®Google Scholar
• ChandrakumarSFYeungJInterleukin-17 antagonists in the treatment of psoriasisJ Cutan Med Surg201519210911425775627
   PubMed Web of Science ®Google Scholar
• MeasePJInhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasisCurr Opin Rheumatol201527212713325599143
   PubMed Web of Science ®Google Scholar